Immunome, Inc. (NASDAQ:IMNM) CTO Buys $103,566.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai purchased 12,300 shares of Immunome stock in a transaction that occurred on Monday, March 24th. The shares were bought at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the transaction, the chief technology officer now directly owns 33,300 shares in the company, valued at $280,386. This represents a 58.57 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Immunome Stock Performance

IMNM opened at $7.09 on Thursday. Immunome, Inc. has a 1-year low of $6.94 and a 1-year high of $26.70. The company has a 50-day moving average of $9.61 and a 200-day moving average of $11.41. The company has a market capitalization of $616.48 million, a P/E ratio of -0.87 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, sell-side analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of Immunome

Several institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in shares of Immunome during the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS bought a new position in Immunome during the 4th quarter worth $75,000. AlphaQuest LLC grew its stake in Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after buying an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after buying an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in Immunome in the fourth quarter valued at $95,000. Institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on IMNM shares. Lifesci Capital initiated coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Guggenheim decreased their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Stephens reiterated an “overweight” rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.